Kemal Malik Net Worth

Kemal Malik biography

Dr. Kemal Malik serves as Independent Director of the Company. He has served as a member of our Board of Directors since January 2020. From February 2014 to December 2019, Dr. Malik served on the Board of Management of Bayer AG and was responsible for Innovation and the Asia/Pacific Regions. Dr. Malik joined Bayer in 1995 as Head of Metabolism and Oncology Europe in the then Pharmaceuticals Business Group. He subsequently served as Head of Global Medical Development before being appointed Head of Global Development and a member of the Executive Committee of Bayer Healthcare AG until his appointment to the Board of Management of Bayer AG. Dr. Malik received his Bachelor of Medicine, Bachelor of Surgery from the University of London. Malik's experience as a leader in the pharmaceutical industry and his extensive clinical development experience qualify him to serve as a member of our Board of Directors.

How old is Kemal Malik?

Kemal Malik is 57, he's been the Independent Director of Acceleron Pharma Inc since 2020. There are 6 older and 4 younger executives at Acceleron Pharma Inc. The oldest executive at Acceleron Pharma Inc is Jay Backstrom, 65, who is the Executive Vice President - Research and Development.

Insiders trading at Acceleron Pharma Inc

Over the last 11 years, insiders at Acceleron Pharma Inc have traded over 211,038,855$ worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth 172,392,007$ . The most active insiders traders include Corp /De/ Celgene、Richard F Pops、Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of 7,646,210$. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth 132,165$.

What does Acceleron Pharma Inc do?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron Pharma Inc executives and stock owners

Acceleron Pharma Inc executives and other stock owners filed with the SEC include:

• Habib Dable,
  President, Chief Executive Officer, Director
• Kevin McLaughlin,
  Chief Financial Officer, Senior Vice President, Treasurer
• Sujay Kango,
  Executive Vice President and Chief Commercial Officer
• Ravindra Kumar,
  Senior Vice President, Chief Scientific Officer
• Francois Nader,
  Independent Chairman of the Board
• Joseph Zakrzewski,
  Independent Director
• Terrence Kearney,
  Independent Director
• Thomas McCourt,
  Independent Director
• Karen Smith,
  Independent Director
• Todd James,
  Senior Vice President Corporate Affairs and Investor Relations
• Kemal Malik,
  Independent Director
• Christopher Hite,
  Director
• Laura Hamill,
  Director
• Jay Backstrom,
  Executive Vice President - Research and Development
• Terrance Mcguire,
  Director
• Tom Maniatis,
  Director
• Jean George,
  Director
• John L Knopf,
  CEO and President
• Steven D Ertel,
  SVP & Chief Business Officer
• Matthew L Sherman,
  SVP & Chief Medical Officer
• Richard F Pops,
  Director
• Adam M Veness,
  SVP, General Counsel and Sec.
• John D Quisel,
  EVP, Chief Business Officer
• Christopher Rovaldi,
  SVP, Program Mgmt and Ops
• Robert K Zeldin,
  EVP & Chief Medical Officer
• Corp /De/ Celgene,
  10% owner
• Anthony B Evnin,
  Director
• Edwin M Jr Kania,
  Director
• Venture Management Co Iv Ll...,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcorbimed Capital...,
  
• Corp /De/Bristol Myers Squi...,